Copyright © 2023 KLCRO, All rights reserved.
Menu
Menu
The majority of clinical trials are in the fields of oncology and hematology, however obtaining regulatory permission is a difficult and risky process. And the search for solutions is urgent for the millions of individuals who receive a cancer diagnosis every year.
Although developments in clinical research in oncology and hematology give patients optimism, they can also pose difficulties for medication developers, such as:
Many Studies
Diversity of Patients
Multiple sites
Around the Globe
Our innovative approaches and state-of-the-art technology enable our committed staff to generate reliable and strong outcomes with the least amount of inconvenience to patients and trial participants. We provide a whole range of end-to-end solutions, such as utilising adaptive trial design strategies and modifying control arms in the middle as required by preliminary results.
We provide medication developers of all sizes with a comprehensive range of end-to-end solutions so they can:
Access a wide range of reliable and customizable resources to support key functional areas, fill gaps in internal capabilities or enhance functional expertise.
Move your molecule to a medicine with an experienced, reliable CDMO partner that offers proven processes for large and small molecules
World-class scientific expertise and industry-leading technologies provide comprehensive, fast and accurate lab services
Leverage a team of oncology experts to build or optimize planning and design scenarios and recruit patients and support sites
Dedicated peri- and post-approval services that translate favorable pre-approval clinical trial results into real-world success
Within the field of oncology, our CRO is proficient in managing clinical trials involving a broad range of cancer types, including hematologic malignancies and solid tumors. We employ state-of-the-art techniques and our wealth of knowledge to investigate new therapy modalities, such as immunotherapies, combination regimens, and targeted medicines. Our dedication to patient-centered care guarantees that cancer trial participants get the best care possible at every stage of their journey.
KLCRO Laboratory services provide the high-quality data required for prompt, precise decision-making at every stage. Our portfolio in hematology/oncology includes:
Antibody-drug conjugates (ADCs)
Biologics
Biomarkers
Companion diagnostics
Small molecules